Cargando…
Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic effic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780658/ https://www.ncbi.nlm.nih.gov/pubmed/35056979 http://dx.doi.org/10.3390/pharmaceutics14010083 |
_version_ | 1784637898555916288 |
---|---|
author | Cho, Hanhee Shim, Man Kyu Yang, Suah Song, Sukyung Moon, Yujeong Kim, Jinseong Byun, Youngro Ahn, Cheol-Hee Kim, Kwangmeyung |
author_facet | Cho, Hanhee Shim, Man Kyu Yang, Suah Song, Sukyung Moon, Yujeong Kim, Jinseong Byun, Youngro Ahn, Cheol-Hee Kim, Kwangmeyung |
author_sort | Cho, Hanhee |
collection | PubMed |
description | Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine. |
format | Online Article Text |
id | pubmed-8780658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87806582022-01-22 Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy Cho, Hanhee Shim, Man Kyu Yang, Suah Song, Sukyung Moon, Yujeong Kim, Jinseong Byun, Youngro Ahn, Cheol-Hee Kim, Kwangmeyung Pharmaceutics Article Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine. MDPI 2021-12-29 /pmc/articles/PMC8780658/ /pubmed/35056979 http://dx.doi.org/10.3390/pharmaceutics14010083 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cho, Hanhee Shim, Man Kyu Yang, Suah Song, Sukyung Moon, Yujeong Kim, Jinseong Byun, Youngro Ahn, Cheol-Hee Kim, Kwangmeyung Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title_full | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title_fullStr | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title_full_unstemmed | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title_short | Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy |
title_sort | cathepsin b-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780658/ https://www.ncbi.nlm.nih.gov/pubmed/35056979 http://dx.doi.org/10.3390/pharmaceutics14010083 |
work_keys_str_mv | AT chohanhee cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT shimmankyu cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT yangsuah cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT songsukyung cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT moonyujeong cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT kimjinseong cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT byunyoungro cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT ahncheolhee cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy AT kimkwangmeyung cathepsinboverexpressedtumorcellactivatablealbuminbindingdoxorubicinprodrugforcancertargetedtherapy |